2024 Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

2024 Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

  • July 2020 •
  • 1273 pages •
  • Report ID: 5877943 •
  • Format: PDF
2024 Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

This new 1,273-page comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years.

The report is available by section, and can be customized to specific information needs and budget. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

The $45 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.  

Table of Contents

I.       Introduction

II.      Worldwide Technology and Market Overview

          A.  DNA Sequencing
             
          B.  DNA and RNA Probes Technology
             
          C.  Detection technologies
             
          D.  Instrumentation Review
                        
          E.  Biochips: Genosensors, Microarrays, and Labs-on-the-Chip

          F.  Pharmacogenomics

          G.  Major Applications

III.     France

IV.     Germany

V.      Italy

VI.     Spain

VII.    U.K.

VIII.   Major Product Development Opportunities

IX.     Design Criteria for Decentralized Testing Products

X.      Alternative Market Penetration Strategies

XI.     Potential Market Entry Barriers and Risks

XII.    Competitive Assessments

XIII.   Appendix

Contains 1,273 pages and 139 tables

Companies Profiled

Competitive Assessments

- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Biotest
- Cepheid
- Decode Genetics
- Diadexus
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Grifols
- Hologic
- Illumina
- LabCorp
- Leica Biosystems
- Li-Cor Biosciences
- Myriad Genetics
- Ortho-Clinical Diagnostics
- PerkinElmer
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens Healthineers
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher